Tela Bio, Inc. Stock Price, News & Analysis

TELA Bio (NASDAQ: TELA) has announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, designed specifically for laparoscopic and robotic-assisted inguinal hernia repair. This launch follows its successful U.S. introduction in 2024, where it generated over $1 million in first-year sales. The product is available in two configurations (three- or four-layer anatomically shaped) and builds on the existing OviTex portfolio, utilizing ovine rumen with minimal polymer content. OviTex has demonstrated strong clinical efficacy with over 69,000 implantations and 40+ published works over 8 years. A notable retrospective study of 259 patients showed a low 1.2% recurrence rate with an average 1.5-year follow-up. The product will be showcased at the European Hernia Society Annual Congress in Paris.

TELA Bio has appointed Jeffrey Blizard as President, effective immediately. Blizard, who has served on TELA Bio's Board of Directors for the past year, joins from Abiomed (a Johnson & Johnson company) where he was Global Head of Surgical Sales. His appointment strengthens TELA Bio's executive leadership team as the medical technology company enters its next growth phase. Blizard brings significant industry experience from leading medtech companies including Medtronic, Intuitive Surgical, and Boston Scientific. Under his leadership at Abiomed, the Surgical Division experienced substantial growth. CEO Antony Koblish expressed confidence that Blizard's proven track record in scaling businesses and team leadership will enhance TELA Bio's market competitiveness and drive commercial performance.

TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's management team will deliver a presentation on June 5th, 2025, at 11:05 am ET. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at ir.telabio.com.

TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of restricted stock units (RSUs) covering 6,600 shares of common stock, awarded to twelve newly-hired employees with a grant date of May 5, 2025. These RSUs, granted under Nasdaq Rule 5635(c)(4), will vest in equal annual installments over a four-year period, contingent on continued employment with TELA Bio.

TELA Bio (TELA) reported Q1 2025 financial results with revenue of $18.5 million, representing 12% year-over-year growth and 5% sequential growth. The company's OviTex and OviTex PRS products saw revenue increases of 15% and 2% respectively. TELA Bio launched larger-sized OviTex PRS for plastic and reconstructive surgery.

Gross profit reached $12.5 million (67.6% margin), while operating expenses decreased to $22.9 million. The company reported a net loss of $11.3 million. Cash and equivalents stood at $42.8 million as of March 31, 2025. TELA Bio reiterated its 2025 revenue guidance of $85.0-88.0 million, projecting 23-27% growth, with operating expenses expected to remain flat compared to 2024.

TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring management discussions on financial performance and corporate updates.

Interested investors must register for the conference call at least 15 minutes before it begins. The event will be accessible through a live webcast and replay via the Events & Presentations section of TELA's investor website.

TELA Bio (NASDAQ: TELA) has announced the U.S. commercial launch of larger sizes of OviTex® PRS Reinforced Tissue Matrix for plastic and reconstructive surgery. The expanded portfolio now includes a 25 x 30 cm oval and a 25 cm diameter circle, offering larger options than any human acellular dermal matrix product currently available.

The company reports significant growth with OviTex PRS, having sold nearly 15,000 units since its 2019 launch, achieving 31% year-over-year unit sales growth in 2024. The larger configurations aim to reduce the need for multiple smaller pieces during complex procedures, potentially improving surgical efficiency and reducing costs.

TELA Bio reported its Q4 and full year 2024 financial results, achieving $17.6 million in Q4 revenue (+4% YoY) and $69.3 million for full year 2024 (+19% YoY). The company saw significant growth in unit sales volume for OviTex® and OviTex PRS products, up 33% and 31% respectively.

The newly launched OviTex IHR Reinforced Tissue Matrix sold over 1,200 units since its mid-April 2024 debut. Q4 gross profit was $11.2 million (64% margin), down from 68% in Q4 2023. Full year 2024 net loss improved to $37.8 million from $46.7 million in 2023.

Looking ahead, TELA Bio projects 2025 revenue guidance of $85.0-88.0 million, representing 23-27% growth, with Q1 2025 expected at $17.0-18.0 million. The company ended 2024 with $52.7 million in cash and expects 2025 operating expenses to remain flat compared to 2024.

TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 20, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring management's discussion of financial results and a corporate update. Interested investors must register in advance or at least 15 minutes before the call. Access to the live webcast and replay will be available through the Events & Presentations page in TELA's investor section website.